[Featured Stock] Dreamtech, Electronic Nose for Asymptomatic COVID-19 Detection... Evolution of High-Margin Smart Medical Devices

[Asia Economy Reporter Hyungsoo Park] Dreamtech is showing strong performance. Securities firms' analysis that the growth potential of the new healthcare business division is significant appears to be influencing the stock price.

At 9:49 a.m. on the 15th, Dreamtech was trading at 12,650 KRW, up 5.86% from the previous day. During the session, it rose to 13,550 KRW, setting a new 52-week high.

Researcher Byunghwa Lee of KB Securities explained, "Dreamtech supplies capacitive fingerprint recognition modules for Samsung Electronics' Galaxy Fold 2," adding, "Along with stable growth in its core business, it is diversifying into the smart medical device sector."

He continued, "With the addition of the high-margin smart medical device business to the low-margin manufacturing sector, we expect concrete improvements in both the quality and quantity of earnings," and added, "we continuously focus on the growth potential of the new healthcare business division."

Furthermore, "We anticipate concrete results in medical device sensors and COVID-19 infection identification solutions," he emphasized, "The electronic nose solution is a device that analyzes chemical components through smell, and it was jointly developed last month with Israel's Nanoscent."

He noted, "We are paying close attention to whether there will be visible sales expansion following the European Union safety certification approval and U.S. Food and Drug Administration (FDA) approval in the third quarter of this year," and predicted, "Once commercialized, the electronic nose solution will be utilized not only in the healthcare industry but also in various fields such as hazardous gas detection."

The electronic nose solution jointly developed by Dreamtech and Nanoscent is a technology that can determine virus infection status within 30 seconds through the subject's exhaled breath. It measures unique volatile organic compounds (VOCs) emitted in breath using nanoparticles, making it faster and more convenient than existing temperature checks or diagnostic kits. It can also screen for infection in asymptomatic individuals during the virus incubation period.

The researcher also introduced, "We are continuously developing wireless biosensors," and said, "The wireless electrocardiogram sensor obtained FDA approval in June 2018 and is scheduled for domestic commercialization in the second half of this year."

He expressed expectations for concrete results in new businesses such as sensors for artificial joint surgery.

This content was produced with the assistance of AI translation services.